Baldwin Brothers Incma Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Baldwin Brothers Incma reduced its stake in Amgen by 13.25% during the most recent quarter end. The investment management company now holds a total of 63,926 shares of Amgen which is valued at $11,060,477 after selling 9,764 shares in Amgen , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Amgen makes up approximately 2.21% of Baldwin Brothers Incma’s portfolio.

Other Hedge Funds, Including , Darrell King reduced its stake in AMGN by selling 5,670 shares or 2.81% in the most recent quarter. The Hedge Fund company now holds 196,192 shares of AMGN which is valued at $33,945,140. Amgen makes up approx 6.09% of Darrell King’s portfolio.Hartford Investment Management Co reduced its stake in AMGN by selling 4,674 shares or 2.44% in the most recent quarter. The Hedge Fund company now holds 186,717 shares of AMGN which is valued at $30,933,405. Amgen makes up approx 0.63% of Hartford Investment Management Co’s portfolio.

Amgen opened for trading at $174.44 and hit $175.99 on the upside on Tuesday, eventually ending the session at $174.4, with a gain of 0.03% or 0.05 points. The heightened volatility saw the trading volume jump to 23,76,437 shares. Company has a market cap of $130,514 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *